After two years of negotiations, the US government has enacted the FDA Reauthorization Act of 2017, or FDARA, that enables the agency to continue using medical device, drug and other health product user fees as a key source of funding through 2022.
Get the full story here at the Emergo Group’s blog.
The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.
The post What FDA medical device user fee reauthorization means for registrants appeared first on MassDevice.
from MassDevice http://ift.tt/2g84SVo
Cap comentari:
Publica un comentari a l'entrada